Having trouble accessing articles? Reset your cache.

Sanofi's Aubagio meets primary in trial to prevent conversion to MS

Sanofi (Euronext:SAN; NYSE:SNY) said once-daily oral Aubagio teriflunomide met the primary endpoint vs. placebo in the Phase III

Read the full 182 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE